[go: up one dir, main page]

DK1120114T3 - Kompositioner og fremgangsmåder til behandling af tilstande, som reagerer på östrogen - Google Patents

Kompositioner og fremgangsmåder til behandling af tilstande, som reagerer på östrogen

Info

Publication number
DK1120114T3
DK1120114T3 DK01300221T DK01300221T DK1120114T3 DK 1120114 T3 DK1120114 T3 DK 1120114T3 DK 01300221 T DK01300221 T DK 01300221T DK 01300221 T DK01300221 T DK 01300221T DK 1120114 T3 DK1120114 T3 DK 1120114T3
Authority
DK
Denmark
Prior art keywords
estrogen
compositions
methods
treatment
administration
Prior art date
Application number
DK01300221T
Other languages
Danish (da)
English (en)
Inventor
David Duane Thompson
Andrew George Lee
Wesley Warren Day
Robert Louis Rosati
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1120114T3 publication Critical patent/DK1120114T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
DK01300221T 2000-01-12 2001-01-11 Kompositioner og fremgangsmåder til behandling af tilstande, som reagerer på östrogen DK1120114T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17575200P 2000-01-12 2000-01-12

Publications (1)

Publication Number Publication Date
DK1120114T3 true DK1120114T3 (da) 2007-02-05

Family

ID=22641493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01300221T DK1120114T3 (da) 2000-01-12 2001-01-11 Kompositioner og fremgangsmåder til behandling af tilstande, som reagerer på östrogen

Country Status (20)

Country Link
US (2) US6632834B2 (xx)
EP (1) EP1120114B1 (xx)
JP (1) JP2001213776A (xx)
KR (1) KR100402563B1 (xx)
AT (1) ATE345794T1 (xx)
AU (1) AU780142B2 (xx)
CA (3) CA2475413A1 (xx)
CO (1) CO5271709A1 (xx)
CY (1) CY1106272T1 (xx)
DE (1) DE60124600T2 (xx)
DK (1) DK1120114T3 (xx)
ES (1) ES2274853T3 (xx)
HU (1) HUP0100120A3 (xx)
IL (1) IL140802A (xx)
MY (1) MY133571A (xx)
NZ (1) NZ509321A (xx)
PE (1) PE20011046A1 (xx)
PT (1) PT1120114E (xx)
TW (1) TWI246918B (xx)
ZA (1) ZA200100177B (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US6916495B2 (en) * 1999-02-24 2005-07-12 Allan Taylor Preparation for regulating lower bowel function
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US20080172047A1 (en) * 2000-12-28 2008-07-17 Palomar Medical Technologies, Inc. Methods And Devices For Fractional Ablation Of Tissue
ES2274915T3 (es) * 2000-12-28 2007-06-01 Palomar Medical Technologies, Inc. Aparato de tratamiento por radiacion electromagnetica (emr) de la piel.
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
BR0312430A (pt) 2002-06-19 2005-04-26 Palomar Medical Tech Inc Método e aparelho para tratamento de condições cutâneas e subcutâneas
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
WO2004064832A2 (en) * 2003-01-22 2004-08-05 Pfizer Products Inc. Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070403A1 (en) * 2004-01-23 2005-08-04 Creighton University Anti-estrogens and methods of use
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
US8071287B2 (en) 2005-04-22 2011-12-06 Liggett Stephen B Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase Polymorphism in asthma and reversible bronchial obstruction
US8346347B2 (en) * 2005-09-15 2013-01-01 Palomar Medical Technologies, Inc. Skin optical characterization device
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9078888B2 (en) * 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
KR102238108B1 (ko) * 2010-11-10 2021-04-12 인리젠 장기 확대를 위한 주사가능 제제
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
WO2014145707A2 (en) 2013-03-15 2014-09-18 Cynosure, Inc. Picosecond optical radiation systems and methods of use
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
JP6899504B2 (ja) * 2017-01-10 2021-07-07 ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
KR102627248B1 (ko) 2018-02-26 2024-01-19 싸이노슈어, 엘엘씨 Q-스위치드 캐비티 덤핑 서브 나노초 레이저
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
CN114901277B (zh) 2019-12-20 2024-05-17 C4医药公司 用于egfr降解的异吲哚啉酮和吲唑化合物
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
CN119998285A (zh) 2022-08-03 2025-05-13 百时美施贵宝公司 用于调控ret蛋白的化合物
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
FR2745182B1 (fr) 1996-02-22 1998-06-19 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant un extrait de solanum lycocarpum
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW403736B (en) 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity
PL338555A1 (en) 1997-08-15 2000-11-06 Univ Duke Method of preventing or treating oestrogen-dependent diseases and disorders
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1246814B1 (en) * 1999-12-30 2005-02-16 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2002003990A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts

Also Published As

Publication number Publication date
CA2331053A1 (en) 2001-07-12
HUP0100120A2 (en) 2002-10-28
CA2475393A1 (en) 2001-07-12
PT1120114E (pt) 2007-01-31
IL140802A (en) 2006-08-01
PE20011046A1 (es) 2001-10-19
CO5271709A1 (es) 2003-04-30
DE60124600T2 (de) 2007-04-05
CY1106272T1 (el) 2011-10-12
MY133571A (en) 2007-11-30
HUP0100120A3 (en) 2004-06-28
EP1120114A3 (en) 2003-08-20
CA2475413A1 (en) 2001-07-12
IL140802A0 (en) 2002-02-10
ZA200100177B (en) 2002-07-08
AU1367601A (en) 2001-07-19
ATE345794T1 (de) 2006-12-15
EP1120114A2 (en) 2001-08-01
AU780142B2 (en) 2005-03-03
KR20010103559A (ko) 2001-11-23
US20040092506A1 (en) 2004-05-13
ES2274853T3 (es) 2007-06-01
CA2331053C (en) 2005-10-25
JP2001213776A (ja) 2001-08-07
HU0100120D0 (en) 2001-03-28
TWI246918B (en) 2006-01-11
EP1120114B1 (en) 2006-11-22
US6632834B2 (en) 2003-10-14
NZ509321A (en) 2002-10-25
KR100402563B1 (ko) 2003-10-17
US20010041718A1 (en) 2001-11-15
DE60124600D1 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
DK1120114T3 (da) Kompositioner og fremgangsmåder til behandling af tilstande, som reagerer på östrogen
MY133564A (en) Compositions and methods for treating osteoporosis and lowering cholesterol
DK1149579T3 (da) Anvendelse af en östrogenagonist/antagonist til behandling af seksualforstyrrelse hos kvinder
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
ATE383856T1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim- derivative als östrogenagentien
DE69728585D1 (de) Mittel gegen Juckreiz
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
YU75903A (sh) Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
ATE437853T1 (de) Glucocorticoid-rezeptoren-modulatoren
DK1626974T3 (da) Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
BR0102150A (pt) Isoxazol-sulfonamidas antagonistas de endotelina
NO20044473L (no) Ikke-steroidal progesteron reseptor modulatorer
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
EA200300789A1 (ru) Применение 2-амино-1-(4-гидрокси-3-метансульфонамидофенил)этанола для лечения недержания мочи
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
BR9901566A (pt) Análogos cis-delta4 de prostaglandinas como hipotensores oculares
ATE363481T1 (de) Pyrazolderivate als gnrh-inhibitoren